Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z8RH
|
||||
| Former ID |
DNC009065
|
||||
| Drug Name |
2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H15F3N2
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)CN2C(=C3C=CC=C(C3=N2)C(F)(F)F)C4=CC=CC=C4
|
||||
| InChI |
1S/C21H15F3N2/c22-21(23,24)18-13-7-12-17-19(18)25-26(14-15-8-3-1-4-9-15)20(17)16-10-5-2-6-11-16/h1-13H,14H2
|
||||
| InChIKey |
LGRUCHCYEMOENE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Oxysterols receptor LXR-alpha | Target Info | Inhibitor | [1] | |
| Oxysterols receptor LXR-beta | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | PPAR signaling pathway | ||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Hepatitis C | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | |||||
| PPAR Alpha Pathway | |||||
| Liver X Receptor Pathway | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Nuclear ReceptorsWP1982:SREBP signalling | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.